Varian Medical Systems Investor Presentation — April 2018

Document content

Senior Vice President, Investor Relations

investors@varian.comApril 25, 2018Second Quarter

This presentation is intended exclusively for investors.

It is not intended for use in Sales or Marketing.

2Forward -Looking Statements

Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements

concerning industry outlook, including growth drivers, future trends incancer incidence andtrends incancer treatment needs, demand, innovation andgrowth opportunities ;Varian

Medical System, Inc.’s(”Varian” orthe“company”) future orders, revenues, backlog orearnings growth ;future financial results ;statements concerning Varian’s planned acquisition

ofSirtex ,expected synergies, accretive expectations, estimated closing date oftheSirtex acquisition, andthecompany’s ability toclose andintegrate theSirtex acquisition and

achieve expected synergies ;market acceptance ofortransition tonew products ortechnology such asourEdge®radiosurgery system, TrueBeam®,HyperArcTM,360OncologyTM,

HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery andproton therapy, andanystatements using theterms “could”, “believe”, “expect”, “outlook”, “anticipate”,

”vision”, “estimate”, “future”, “horizon”, “aiming”, “driving”, “target” orsimilar statements areforward -looking statements that involve risks and uncertainties that could cause the

company’s actual results todiffer materially from those anticipated .Such risks anduncertainties include global economic conditions andchanges totrends forcancer treatment

regionally ;theimpact ofchanges totheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) andanyfurther healthcare reforms (including changes to

Medicare andMedicaid), and/or changes tothird-party reimbursement levels ;currency exchange rates andtaxrates ;theimpact oftheTaxCuts andJobs Act;demand forthe

company’s products ;thecompany’s ability todevelop, commercialize, and deploy new products ;thecompany’s ability tomeet Food andDrug Administration (FDA) andother

regulatory requirements forproduct clearances ortocomply with FDA andother regulatory regulations orprocedures, changes intheregulatory environment, including withrespect

toFDA requirements ;thecompany’s assessment ofthegoodwill associated with itsparticle therapy business, challenges associated with thesuccessful commercialization ofthe

company’s particle therapy business ;therisks associated with providing financing fortheconstruction and start-upoperations ofproton therapy centers ;theeffect ofadverse

publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive products andpricing ;the